Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 36, n° 6
pages 932-934 (juin 1997)
Doi : 10.1016/S0190-9622(97)80275-7
accepted : 7 January 1997
Brief communication

Ranitidine does not affect psoriasis: A multicenter, double-blind, placebo-controlled study

I.M. Zonneveld, MD a, , M.M.H.M. Meinardi, MD a, T. Karlsmark, MD b, U. Broby Johansen, MD b, G.R.R. Kuiters, MD c, L. Hamminga, MD c, B. Staberg, MD d, A.J. van't Veen, MD e, P.M.M. Bossuyt, PhD f, J.C.G. van Niel, PhD g, J.D. Bos, MD a
a Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands 
b Department of Dermatology, Academic Medical Center, Rigshospitalet, Copenhagen, Denmark 
c Department of Dermatology, Academic Medical Center, Zwolle, The Netherlands 
d Department of Dermatology, Academic Medical Center, Roskildevej, Rødovre, Denmark 
e Academic Hospital, Erasmus University of Rotterdam, The Netherlands 
f Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands 
g Medical Department, Glaxo B.V. Amsterdam, The Netherlands 

*Reprint requests: I. M. Zonneveld, MD, Dept. of Dermatology, Academisch Medisch Centrum, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

Data from open studies suggest that ranitidine has a beneficial effect on psoriasis and is well tolerated.


Our purpose was to determine the effectiveness of ranitidine in a 24-week, multicenter, double-blind, placebo-controlled, dose-comparing study of 201 patients with psoriasis.


Patients with moderate to severe psoriasis who had stopped systemic antipsoriatic therapy, including PUVA and UVB, for at least 10 weeks were included. After a washout period of 2 weeks, patients were randomly allocated to use either ranitidine, 150 mg twice a day; ranitidine, 300 mg twice a day; or placebo for up to 24 weeks. Assessment with the Psoriasis Area and Severity Index was performed at weeks 3, 6, 9, 12, 18, and 24 after randomization. Reduction of the Psoriasis Area and Severity Index score by 70% at the completion of the study was considered a treatment success.


The success rates at week 24 in the 300 mg, 600 mg, and placebo groups were 11 %, 5%, and 12%, respectively. No significant differences were observed between the three treatment groups at any stage of the study.


This study provides strong evidence that ranitidine does not affect the skin disease in patients with psoriasis. Supported by Glaxo B. V., Zeist, The Netherlands.

The full text of this article is available in PDF format.

Top of the page

© 1997  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline